Jupiter Topco LLC Buys Shares of 3,408,045 Maze Therapeutics, Inc. $MAZE

Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,408,045 shares of the company's stock, valued at approximately $101,764,000. Jupiter Topco LLC owned about 6.14% of Maze Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the 2nd quarter valued at approximately $122,983,582,000. ADAR1 Capital Management LLC bought a new stake in Maze Therapeutics in the second quarter valued at $10,124,000. Canada Pension Plan Investment Board acquired a new position in shares of Maze Therapeutics during the second quarter valued at $272,000. Legal & General Group Plc bought a new position in shares of Maze Therapeutics during the second quarter worth about $471,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Maze Therapeutics in the 2nd quarter worth about $489,000.

Insider Transactions at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the sale, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider directly owned 26,250 shares of the company's stock, valued at $717,675. This represents a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 108,110 shares of company stock valued at $3,057,531. Corporate insiders own 5.30% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. BTIG Research reissued a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Trading Down 2.8%

Maze Therapeutics stock opened at $29.58 on Thursday. Maze Therapeutics, Inc. has a 12-month low of $13.67 and a 12-month high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The stock has a market capitalization of $1.64 billion, a PE ratio of -11.74 and a beta of 2.21. The firm has a 50 day simple moving average of $28.64 and a 200-day simple moving average of $32.04.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.76). As a group, equities research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source